Aclidinium bromide

(Tudorza Pressair®)

Aclidinium bromide

Drug updated on 11/1/2024

Dosage FormPowder (inhalation; 400 mcg)
Drug ClassAnticholinergics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Aclidinium bromide/Formoterol (AB/FF) demonstrated the highest effectiveness in improving FEV1, with a SUCRA (surface under cumulative rankings) score of 97.7%, surpassing Umeclidinium/vilanterol (UMEC/VI) at 93.5%, Glycopyrrolate Formoterol Fumarate (GFF) at 84.7%, and Dupilumab at 66.9%, which ranked first among monoclonal antibodies (mAbs).
  • The systematic review does not provide specific details regarding differences in effectiveness among various population types or subgroups.
  • No significant safety concerns or adverse effects specific to Aclidinium bromide or its combination with Formoterol are mentioned in the study, although mAbs are indicated to have a good safety profile compared to placebo.
  • Specific safety outcomes for Aclidinium bromide compared to other conventional agents were not detailed in the study.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Tudorza Pressair (aclidinium bromide) Prescribing Information.2022Covis Pharma, Berkeley Heights, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.Global Initiative for Chronic Obstructive Lung Disease
Global strategy for prevention, diagnosis and management of COPD.Global Initiative for Chronic Obstructive Lung Disease